PAVmed Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
PAVM$1.56-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net income (loss) - before noncontrolling interest (“NCI”) | $28,427 | $(79,263) |
| Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities | ||
| Depreciation and amortization expense | 1,198 | 2,932 |
| Stock-based compensation | 6,449 | 11,139 |
| Gain on sale of intellectual property | — | (1,000) |
| Gain on deconsolidation of subsidiary | (72,287) | — |
| Change in fair value - equity method investment | (532) | — |
| APA-RDx: Issue common stock of subsidiary - termination payment | — | 713 |
| Amortization of common stock payment for vendor service agreement | 598 | 625 |
| Change in fair value - Senior Secured Convertible Notes | (462) | 6,026 |
| Loss on issue - Senior Secured Convertible Note | — | 1,111 |
| Debt extinguishment loss - Senior Secured Convertible Note | 2,535 | 3,782 |
| Non-cash lease expense | 8 | 308 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 43 | (44) |
| Prepaid expenses, deposits and current and other assets | 832 | (246) |
| Accounts payable | (59) | (918) |
| Accrued expenses and other current liabilities | (304) | 2,799 |
| Net cash flows used in operating activities | (33,554) | (52,036) |
| Cash flows from investing activities | ||
| Purchase of equipment | (55) | (242) |
| Decrease in cash due to deconsolidation of subsidiary | (16,479) | — |
| Proceeds from sale of intellectual property to Lucid Diagnostics Inc. | 350 | — |
| Proceeds from sale of intellectual property | — | 1,000 |
| Net cash flows provided by (used in) investing activities | (16,184) | 758 |
| Cash flows from financing activities | ||
| Proceeds – issue of preferred stock - subsidiary | 29,798 | 18,625 |
| Proceeds – issue of Senior Secured Convertible Note | — | 10,000 |
| Payment – Senior Secured Convertible Note – acceleration floor payments | (531) | (79) |
| Proceeds – issue of common stock - At-The-Market Facility | 1,598 | 1,533 |
| Proceeds – subsidiary common stock - Committed Equity Facility and At-The-Market Facility | — | 284 |
| Proceeds – issue common stock – Employee Stock Purchase Plan | 62 | 259 |
| Proceeds – subsidiary common stock – Employee Stock Purchase Plan | 353 | 551 |
| Proceeds – exercise of stock options issued under equity plan of subsidiary | 4 | — |
| Net cash flows provided by financing activities | 31,284 | 31,173 |
| Net increase (decrease) in cash | (18,454) | (20,105) |
| Cash, beginning of period | 19,639 | 39,744 |
| Cash, end of period | $1,185 | $19,639 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.